Kestra Medical Technologies Inc. is $196 million in the black, having closed an oversubscribed funding round that will help the firm expand its commercial operation and further promote its modern wearable cardioverter defibrillator (WCD).

凯斯特拉医疗技术有限公司（KestraMedical Technologies Inc.）拥有1.96亿美元的资金，完成了一轮超额认购的融资，这将有助于该公司扩大其商业运营，并进一步推广其现代可穿戴式心脏复律除颤器（WCD）。

Financial support came from Andera Partners, Ally Bridge Group, Longitude Capital and Omega Funds with participation from new investors, funds and accounts advised by T. Rowe Price Investment Management Inc., Eventide Asset Management, and Gilmartin Capital. Long-term investors Bain Capital and Endeavour Vision also participated with significant contributions..

资金支持来自Andera Partners、Ally Bridge Group、Longitude Capital和Omega Funds，新投资者、T.Rowe Price Investment Management Inc.、Eventide Asset Management和Gilmartin Capital建议的基金和账户也参与其中。长期投资者贝恩资本（Bain Capital）和奋进愿景（Endeavor Vision）也参与了此次投资，并做出了重大贡献。。

'This oversubscribed financing is validation of the excitement and confidence that new and existing investors have for Kestra and our ASSURE cardiac recovery system which has been prescribed to well over 10,000 patients to date. With this funding, our team is ready to aggressively compete and accelerate our commercialization initiatives to transform the WCD market with our clinically proven system,' Kestra Medical Technologies President/CEO Brian Webster said..

“这种超额认购的融资证实了新投资者和现有投资者对凯斯特拉和我们的ASSURE心脏康复系统的兴奋和信心，该系统迄今已为10000多名患者开出处方。Kestra Medical Technologies总裁/首席执行官布莱恩·韦伯斯特（BrianWebster）说：“有了这笔资金，我们的团队准备积极竞争并加速我们的商业化举措，以我们经过临床验证的系统改造WCD市场。”。。

The ASSURE system represents the next generation of cardiac monitoring and defibrillation therapy. Besides providing autonomous detection and defibrillation for ventricular arrhythmias, it can also detect and record other clinically significant arrhythmias that may require clinical intervention. Kestra claims it offers the only option designed specifically to meet the underserved needs of female cardiac patients.

ASSURE系统代表了下一代心脏监测和除颤治疗。除了为室性心律失常提供自主检测和除颤外，它还可以检测和记录可能需要临床干预的其他临床上显着的心律失常。凯斯特拉声称，它是专门为满足女性心脏病患者服务不足的需求而设计的唯一选择。

The ASSURE system has established U.S. reimbursement and broad insurance coverage..

ASSURE系统建立了美国报销和广泛的保险范围。。

“We are impressed with the clinical performance of the Kestra technology, their patient-focused approach and moreover, the opportunity to penetrate this large and growing patient population,” said Aneta Sottil, a partner at Andera Partners. “We are keen to partner with Kestra and their team as they work to disrupt the existing $1 billion WCD market.”.

Andera Partners的合伙人Aneta Sottil说：“我们对Kestra技术的临床表现、以患者为中心的方法以及渗透这一庞大且不断增长的患者群体的机会印象深刻。”。“我们渴望与凯斯特拉及其团队合作，以打破现有的10亿美元WCD市场。”。

With four channels of ECG, an advanced algorithm and adaptive patient intelligence, the ASSURE WCD reduces noise and ensures clear data and insights. ASSURE is the only WCD system that offers additional support by sending an alert through the ASSURE patient application to an emergency medical services (EMS) operator after a defibrillation shock..

ASSURE WCD具有四通道心电图、先进算法和自适应患者智能，可减少噪音并确保清晰的数据和见解。ASSURE是唯一一个在除颤电击后通过ASSURE患者应用程序向紧急医疗服务（EMS）操作员发送警报来提供额外支持的WCD系统。。

The complete Cardiac Recovery System includes the ASSURE WCD, the recently U.S. Food and Drug Administration-cleared ASSURE Wearable ECG, the ASSURE patient app, ASSURE Assist Services and the Kestra CareStation remote patient data platform. All components of the system work together to provide comfortable protection for patients, improved compliance, and clear insights for healthcare providers..

完整的心脏恢复系统包括ASSURE WCD、最近美国食品和药物管理局批准的ASSURE可穿戴心电图、ASSURE patient app、ASSURE Assist Services和Kestra CareStation远程患者数据平台。该系统的所有组件协同工作，为患者提供舒适的保护，提高依从性，并为医疗保健提供者提供清晰的见解。。

“We are proud to continue our long-time support of Kestra and its people-driven mission to protect patients with technologies that are intuitive, intelligent, and mobile,” Bain Capital Partner Chris Gordon stated. “We welcome the support of the new investors and look forward to continuing to back Brian and his strong team as they continue to deliver lifesaving products and services that make a difference in patients’ lives.”.

贝恩资本合伙人克里斯·戈登（ChrisGordon）表示：“我们很自豪能够继续长期支持凯斯特拉及其以人为本的使命，以直观、智能和移动的技术保护患者。”。“我们欢迎新投资者的支持，并期待着继续支持Brian及其强大的团队，因为他们将继续提供挽救生命的产品和服务，从而改变患者的生活。”。

In conjunction with the financing, Kevin Reilly from Ally Bridge Group, Maxwell Bikoff from Longitude Capital, and Francesco Draetta from Omega Funds will join Kestra's Board of Directors.

在融资方面，Ally Bridge Group的Kevin Reilly、Longitude Capital的Maxwell Bikoff和Omega Funds的Francesco Draetta将加入Kestra的董事会。

BofA Securities acted as sole placement agent for this transaction.

美国银行证券作为此次交易的独家配售代理。

Kestra Medical Technologies Inc. is a privately held wearable medical device and digital healthcare company that develops diagnostic monitoring and therapeutic technologies that are intuitive, intelligent, and mobile. Kestra was founded in 2014 by Bain Capital private equity and leaders from the external (AED) and internal (ICD) defibrillation industries. .

Kestra Medical Technologies Inc.是一家私营可穿戴医疗设备和数字医疗保健公司，开发直观、智能和移动的诊断监测和治疗技术。凯斯特拉成立于2014年，由贝恩资本私人股本公司（Bain Capital private equity）和外部（AED）和内部（ICD）除颤行业的领导者共同创立。。